06:45 AM EST, 12/18/2025 (MT Newswires) -- MediciNova ( MNOV ) said Thursday it has completed patient enrollment in its phase 2 study evaluating MN-166 for the prevention of chemotherapy-induced peripheral neuropathy in patients with metastatic colorectal cancer.

The company said a total of 100 patients were enrolled across two treatment arms at 11 clinical sites in Australia.

Participants will continue chemotherapy alongside the assigned study drug until disease progression or unacceptable side effects, the company said, adding that the study will conclude when the last patient reaches six months post-chemotherapy, with topline data expected later in 2026.